Jazz Pharmaceuticals (JAZZ) Tops Q2 EPS by 53c

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $5.30, $0.53 better than the analyst estimate of $4.77. Revenue for the quarter came in at $1.02 billion versus the consensus estimate of $1 billion.

GUIDANCE:

Jazz Pharmaceuticals sees FY2024 EPS of $19.20-$20.30, versus the consensus of $18.51. Jazz Pharmaceuticals sees FY2024 revenue of $4-4.1 billion, versus the consensus of $4.05 billion.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Prologis makes unsolicited bid for SEGRO, valued at £12.6 billion
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance